Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
August 15, 2016
- JT/Torii License Menlo’s Pruritus Candidate for Japan Market
August 15, 2016
- Sawai Eyes First-to-File Status for 5 Generics in the US
August 10, 2016
- Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
August 10, 2016
- Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
August 10, 2016
- Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
August 10, 2016
- Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
August 10, 2016
- Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
August 10, 2016
- Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
August 10, 2016
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
- Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
August 8, 2016
- Astellas to Transfer US Manufacturing Unit to Avara
August 5, 2016
- Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
August 5, 2016
- Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
August 5, 2016
- Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
August 4, 2016
- Teijin Jettisons Extended-Release Version of Feburic; Successor Now in PI
August 3, 2016
- Mitsubishi Tanabe Erases Alzheimer’s Drug from Japan Pipeline
August 3, 2016
- Adcetris Shows Positive Efficacy Profile in Cutaneous T-Cell Lymphoma
August 3, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…